Liminatus Pharma, Inc. Class A Common Stock
Stock Chart, Company Information, and Scan Results
$1.38(as of Oct 30, 2:49 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Liminatus Pharma, Inc. Class A Common Stock Company Information, Fundamentals, and Technical Indicators
Stock Price$1.38
Ticker SymbolLIMN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
EmployeesUnknown
CountyUSA
Market Cap$145.2M
EBIDTAUnknown
P/E Ratio-23.66
Forward P/E Ratio0.00
Earnings per Share-0.16
Profit MarginInfinity%
RSI43.91
Shares Outstanding26.0M
ATR0.22
52-Week High33.66
Volume839,737
52-Week Low1.11
Book Value-8.8M
P/B Ratio-3.76
Upper Keltner1.90
P/S RatioInfinity
Lower Keltner0.90
Next Earnings DateUnknown
Cash Surplus-9.2M
Next Ex-Dividend DateUnknown
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Liminatus Pharma, Inc. Class A Common Stock In Our Stock Scanner
As of Oct 30, 2025
Scan Name: Mean ReversionScan Type: Stock Indicator Scans
As of ---
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.